Targeted drugs associated with trimethylamine and/or trimethylamine-N-oxideEmbodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.A method for treating a patient suffering from a disorder associated with at least one of trimethylamine (tma), trimethylamine n-oxide (tmao) and derivatives thereof, which comprises administering to the patient suffering from the disorder a therapeutically effective amount of a compound for inhibiting choline trimethylamine lyase (cutc) enzyme derived from at least one of nostoc commune (phylum) and proteobacteria (phylum), wherein the compound comprises at least one of 2-ethyl-1-butanol, (2r) -3, 3-dimethyl-1, 2-butanediol, (2s) -4-methyl-2-pentanol, (2s) -3-methyl-2-butanol, (2r) -4-methyl-2-pentanol, (2r) -3-methyl-2-butanol, (2s) -4-methyl-1, 4-methyl-2-pentanol, (2s) -3-methyl-2-methoxyphenyl- (1, 3-methylphenyl) -2-propion-2-hydroxy-2-phenyl) benzamidine, (2s) -3, 3-methyl-2-ethylheptylamine, (2-3-ethyl-2-benzoylamine, 3, 3-dimethyl-1, 3-2-heptanylamine, (2-s) -3, 3-6- (2-ethyl-2-hydroxy-phenyl) -1, 3-2-phenyl-2-1, 3-2-ethyl-2-1, 3-2-5- (2-ethyl-2-phenyl-2-butanamidine, (2-phenyl-2-ethyl-2-phenyl-2-ethyl-2-ethyl-2-butanol, (2-phenyl-2-ethyl-2-ethyl-2-butanol, (2-phenyl-2-phenyl-ethyl-2-phenyl-2-butanol, 3-2-phenyl-2-butanol, 3-2-phenyl-2-phenyl-2-phenyl-2-phenyl.
트리메틸아민 및/또는 트리메틸아민 N-옥사이드 관련 표적화된 약물방법 및/또는 시스템의 구현예는 TMA, TMAO 및/또는 이의 유도체 중 적어도 하나와 관련된 하나 이상의 컨디션을 갖는 환자에게 미생물 분류군 세트로부터의 적어도 하나의 분류군으로부터의 미생물과 관련된 CutC 효소 및/또는 CntA 효소 중 하나 이상의 억제에 영향을 미치는 치료적 유효량의 화합물을 투여하는 것을 포함할 수 있다.2-에틸-1-부탄올; (2R)-3,3-디메틸-1,2-부탄디올; (2S)-3,3-디메틸-1,2-부탄디올; (2S)-4-메틸-2-펜탄올; (2S)-3-메틸-2-부탄올; (2R)-4-메틸-2-펜탄올; (2R)-3-메틸-2-부탄올; (2S)-2-펜탄올; (2S)-2-메틸-1,4-부탄디올; 2-메틸-2,4-부탄디올; 트리메틸올프로판; 3-(4-메톡시페닐)프로판알; 1-(3-피리디닐)-2-프로판아민; 2-[(2R)-2-부타닐]페놀; 4-프로필벤조산; (2S)-1-(벤질옥시)-2-프로판올; 메틸 3-(4-히드록시페닐)프로파노에이트; α-메틸페닐알라닌; 2,2-디메틸-1-페닐-1-프로판올; 메틸 (2R)-히드록시(페닐)아세테이트; (2S)-2-페닐피롤리디늄; 4-메틸-3-페닐-1,2-옥사졸-5-아민; 4,4'-바이페닐디아민; 4'-메틸-2-바이페닐카르보니트릴; 4-바이페닐올; 2-[3-(4-메틸페닐)-1,2-옥사졸-5-일]에탄올; 4-바이페닐카르복사미드; 4-에티닐바이페닐; 5-(4-메틸페닐)-1H-1,2,4-트리아졸-3-아민; 5-(4-메틸페닐)-1H-피라졸-3-아민; 4-히드록시카테콜; 3-페닐-1H-피라졸-5-카르보히드라지드; 4-메틸-1,3-벤젠디올; N-(2-히드록시에틸)-1,3-프로판디아미늄; 3-메톡시-3-메틸부탄올; 4-피리디닐메탄아미늄; N-메틸-3-피리딘아민; 2-메톡시피리딘; 5-메틸-3-피리딘아민; 1-(4-메틸-3-피리디닐)메탄아민; 메시틸렌; (E)-벤즈알독심' (3R)-2,2,4-트리메틸-1,3-펜탄디올; (1R,4R)-2-아자바이시클로[2.2.1]헵트-2-일아세트산; 3-아세틸페놀; 3-히드록시벤조산; 1H-인돌-7-일메탄올; 3-비닐아닐린; (3s,5s,7s)-1-이소시아네이토아다만틴(이소시아네이토아다만탄); (1R,2S,5R)-2-히드록시-2,6,6-트리메틸바이시클로[3.1.1]헵탄-3-온; (-)-β-피넨; 2H-이소인돌-1,3-디아민; (3s,5s,7s)-1-아다만타놀; (3-아미노바이시클로[2.2.1]헵트-2-일)메탄올; 3-(히드라지노메틸)페놀; (1S,2R)-2-카바모일시클로헥산아미늄; (1S,4R)-1,3,3-트리메틸바이시클로[2.2.1]헵탄-2-온; (1R,4S)-1,3,3-트리메틸바이시클로[2.2.1]헵탄-2-온; 메틸 4-메틸-4-피페리딘카르복실레이트; 메틸 헵타노에이트; 3-메틸피리다진; 4,5-디메틸-1,2-옥사졸-3-아민; 2-(2-히드록시에톡시)페놀; 2-히드록시-N-(3-피리디닐메틸)에탄아미늄; 3-페닐-1-프로판올; (2R)-6-메틸-2-헵타놀; 2-페녹시아세토히드라지드; N-히드록시옥탄아미드; 시클로부탄카르보히드라지드; 페닐히드라진; (1S,4R)-2-아자바이시클로[2.2.1]헵트-5-엔-3-온; 살리실아미드; 아다만탄; 3-아자바이시클로[3.3.1]노네인; N-히드록시-2-메틸벤젠카르복스이미드아미드; (-)-캄펜; (1S,2S,4S)-바이시클로[2.2.1]헵트-5-엔-2-일메탄올; 디시클로펜타디엔; (8-안티)(anti)-3-아자바이시클로[3.2.1]옥탄-8-올; (1R,2S,6R,7S)-트리시클로[5.2.1.02,6]데카-3,8-디엔; 이의 약학적으로 허용되는 형태; 및 이의 염 중 적어도 하나를 포함하는 화합물의 치료학적 유효량을, 피르미쿠테스(Firmicutes)(문) 및 프로테오박테리아(Proteobacteria)(문) 중 적어도 하나로부터의 미생물의 CutC(choline trimethylamine-lyase) 효소 억제를 위해, 트리메틸아민(TMA), 트리메틸아민 N-옥사이드(TMAO), 및 이들의 유도체 중 적어도 하나와 관련된 컨디션을 갖는 환자에게 투여하는 단계를 포함하는, 트리메틸아민(TMA), 트리메틸아민 N-옥사이드(TMAO), 및 이들의 유도체 중 적어도 하나와 관련된 컨디션을 갖는 환자를 치료하는 방법.